Ranibizumab

CAS No. 347396-82-1

Ranibizumab( —— )

Catalog No. M22159 CAS No. 347396-82-1

Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 820 In Stock
10MG 1311 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ranibizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
  • Description
    Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    347396-82-1
  • Formula Weight
    48 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Klettner A, et al.Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7.
molnova catalog
related products
  • Icrucumab

    Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.

  • GW297361

    GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 and Pho85 were 20 nM and 400 nM, respectively.

  • 8-O-Acetylshanzhisid...

    8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.